Trials / Completed
CompletedNCT06009393
Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
A Single-Arm, Open-Label, Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a single-arm, open-label study to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with homozygous familial hypercholesterolemia (HoFH).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1918 | Three administration |
Timeline
- Start date
- 2023-12-22
- Primary completion
- 2024-06-29
- Completion
- 2024-08-23
- First posted
- 2023-08-24
- Last updated
- 2025-09-05
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06009393. Inclusion in this directory is not an endorsement.